4/A: Mural Oncology Director Francis M. Cuss Corrects Stock Option Price in Amended SEC Filing
SEC Filing
Francis M. Cuss, a director at Mural Oncology plc, filed an amended SEC Form 4 to correct a scrivener's error regarding the price of a stock option granted on May 30, 2024.
Summary
- Francis M. Cuss, a director of Mural Oncology plc, filed an amendment to a previously submitted SEC Form 4.
- The amendment corrects the price of a stock option granted to Cuss on May 30, 2024.
- The original filing incorrectly stated the price as $3.35, which has now been corrected.
- The stock option allows Cuss to buy 8,462 ordinary shares.
- The option vests on the earlier of the first anniversary of the grant date or the date of the next Annual Meeting, contingent upon Cuss's continued service with the company.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain any information that would significantly impact investor sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of stock option grant |
| 06/03/2024 | Date of original Form 4 filing |
| 06/05/2024 | Date of amended Form 4/A filing |
| 05/29/2034 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.